• NAUTILUS: Understanding changes in autonomic function in Parkinson’s disease, effects on quality of life, and risk of fainting. [Recruiting soon] 
No active studies. 
  • Liu, S. Y., Wile, D. J., Fu, J. F., Valerio, J., Shahinfard, E., McCormick, S., … & Stoessl, A. J. (2018). The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson’s disease: A cross-sectional PET study. The Lancet Neurology17(4), 309-316.
  • Perez‐Soriano, A., Arena, J. E., Dinelle, K., Miao, Q., McKenzie, J., Neilson, N., … & Stoessl, A. J. (2017). PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. Movement Disorders32(7), 1016-1024.
  • Wile, D. J., Agarwal, P. A., Schulzer, M., Mak, E., Dinelle, K., Shahinfard, E., … & Stoessl, A. J. (2017). Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: Cross-sectional studies. The Lancet Neurology16(5), 351-359.
  • Wile, D. J., Dinelle, K., Vafai, N., McKenzie, J., Tsui, J. K., Schaffer, P., … & Stoessl, A. J. (2016). A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine‐rich repeat kinase 2 mutation carrier. Movement Disorders31(3), 405-409.
No active studies. 
  • Höglinger, G. U., Litvan, I., Mendonca, N., Wang, D., Zheng, H., Rendenbach-Mueller, B., … & Zesiewicz, T. (2021). Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomised, placebo-controlled trial. The Lancet Neurology20(3), 182-192.
  • Martin-Bastida, A., Ward, R.J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., Crichton, R. R., Dexter, D. T. (2017). Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Scientific Reports, 7(1): 1398. doi: 10.1038/s41598-017-01402-2. 
  • FORCE STEADINESS: Upper limb force steadiness in Parkinson’s disease. [Recruiting]
  •             *Those interested in participating in this study can contact the study lead at:  
  • ICEBERG: Effects of upper limb ergometry on hand function in Parkinson’s disease. [Recruiting soon] 
  • Smart, R. R., Toumi, A., Harris, O. D., Cremoux, S., Dalton, B. H., Wile, D. J., & Jakobi, J. M. (2023). Inter-muscular coherence of plantar and dorsiflexor muscles in older adults with Parkinson’s disease and age-matched controls during bipedal and unipedal stance. Frontiers in Aging Neuroscience15, 1093295.
  • Smart, R. R., Richardson, C. M., Wile, D. J., Dalton, B. H., & Jakobi, J. M. (2020). Importance of maximal strength and muscle-tendon mechanics for improving force steadiness in persons with Parkinson’s disease. Brain Sciences10(8), 471.
No active studies. 
  • Peacock, D., Yoneda, J., Thomson, V., & Wile, D. (2021). Tailoring the use of wearable systems and tele-health for Parkinson’s disease. Parkinsonism & Related Disorders, 89, 111-112.
  • Peacock, D., Baumeister, P., Monaghan, A., Siever, J., Yoneda, J., & Wile, D. (2020). Perception of healthcare access and utility of tele-health among Parkinson’s disease patients. Canadian Journal of Neurological Sciences, 47(5), 700-704.
  • Wile, D. J., Ranawaya, R., & Kiss, Z. H. (2014). Smart watch accelerometry for analysis and diagnosis of tremor. Journal of neuroscience methods230, 1-4.

Overview of Publications

A full list of Dr. Daryl Wile's publications can be viewed at the link below.